Albany Molecular Research has begun the process of manufacturing a 200g demonstration batch of psilocybin for Tryp Therapeutics. This is the first step in the company’s plan to manufacture batches of Tryp’s proprietary formulation of cGMP psilocybin, TRP-8802. La Jolla, California–(Newsfile Corp. – February 16, 2021) – Tryp Therapeutics (CSE: TRYP) (“Tryp” or the “Company”) a pharmaceutical…
